



This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).



Physicians' Academy
for Cardiovascular Education

INDUSTRY SESSION ON THE OCCASION OF THE 57TH ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES

Teaming up to tackle cardiorenal risk in diabetes

Role of SGLT2i: How to overcome clinical inertia



TUESDAY, SEPTEMBER 28, 2021 | 17:40 – 18:10 HRS

Supported by an unrestricted educational grant from Boehringer Ingelheim and Lilly Alliance.
The scientific programme has not been influenced in any way by its sponsor.

"In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities."



Boehringer
Ingelheim



Teaming up to tackle cardiorenal risk in diabetes Role of SGLT2i: How to overcome clinical inertia

TUESDAY, SEPTEMBER 28, 2021 | 17:40 - 18:10 HRS

AGENDA

- 17:40 – 17:45 **The case challenge: Teaming up to tackle cardiorenal risk in diabetes**
Melanie Davies, MD – Leicester, United Kingdom
- 17:45 – 17:55 **Defining treatment goals: SGLT2i, implications from clinical trials and guidelines**
Nikolaus Marx, MD – Aachen, Germany
- 17:55 – 18:05 **Practical Challenges: SGLT2i in the spectrum of diabetes, CVD & CKD: Who and how to manage?**
Melanie Davies, MD – Leicester, United Kingdom
- 18:05 – 18:10 **Discussion**
How to overcome clinical inertia?
Nikolaus Marx, MD – Melanie Davies, MD

Educational objectives

- To summarise the epidemiology and pathophysiology of patients with diabetes, CVD and CKD
- To discuss the role of SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiorenal risk
- To address the remaining questions on the role of SGLT2 inhibition in the management of patients with diabetes and cardiorenal complications
- To provide an expert perspective on the clinical management of patients with type 2 diabetes, CKD and CVD